- Home
- GCI vs ANAB Comparison
GCI vs ANAB Comparison
Compare GCI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- ANAB
- Stock Information
- Founded
- GCI 1997
- ANAB 2005
- Country
- GCI United States
- ANAB United States
- Employees
- GCI N/A
- ANAB N/A
- Industry
- GCI Newspapers/Magazines
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- GCI Consumer Discretionary
- ANAB Health Care
- Exchange
- GCI Nasdaq
- ANAB Nasdaq
- Market Cap
- GCI 854.6M
- ANAB 759.5M
- IPO Year
- GCI N/A
- ANAB 2017
- Fundamental
- Price
- GCI $4.97
- ANAB $13.41
- Analyst Decision
- GCI Buy
- ANAB Buy
- Analyst Count
- GCI 2
- ANAB 11
- Target Price
- GCI $5.55
- ANAB $42.67
- AVG Volume (30 Days)
- GCI 1.0M
- ANAB 777.9K
- Earning Date
- GCI 02-20-2025
- ANAB 11-05-2024
- Dividend Yield
- GCI N/A
- ANAB N/A
- EPS Growth
- GCI N/A
- ANAB N/A
- EPS
- GCI N/A
- ANAB N/A
- Revenue
- GCI $2,557,445,000.00
- ANAB $57,172,000.00
- Revenue This Year
- GCI N/A
- ANAB $233.68
- Revenue Next Year
- GCI N/A
- ANAB N/A
- P/E Ratio
- GCI N/A
- ANAB N/A
- Revenue Growth
- GCI N/A
- ANAB 282.17
- 52 Week Low
- GCI $1.95
- ANAB $13.67
- 52 Week High
- GCI $5.93
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- GCI 44.64
- ANAB 29.12
- Support Level
- GCI $4.77
- ANAB $15.11
- Resistance Level
- GCI $5.16
- ANAB $16.74
- Average True Range (ATR)
- GCI 0.32
- ANAB 1.43
- MACD
- GCI -0.03
- ANAB -0.27
- Stochastic Oscillator
- GCI 27.17
- ANAB 1.24
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).